← Back to Search

Non-pharmacological Therapy

MagPro X100 Stimulator, B70 Fluid-Cooled Coil for Depression

N/A
Waitlist Available
Led By Daniel Blumberger, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have unipolar depressive episode based on the MINI with or without psychotic symptoms
Have previous response to ECT or high symptom severity warranting acute ECT in the opinion of a consultant brain stimulation psychiatrist
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks (tapering and relapse prevention phase)
Awards & highlights

Study Summary

This trial is testing a new, high-dose protocol for aiTBS (a type of brain stimulation therapy) in patients with unipolar depression who have responded to ECT in the past, or who urgently need treatment due to symptom severity during the COVID-19 pandemic.

Eligible Conditions
  • Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks (tapering and relapse prevention phase)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks (tapering and relapse prevention phase) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion achieving remission on Hamilton Rating Scale for Depresion 24-it (HRSD-24)
Secondary outcome measures
Change in GAD-7
Change in HRSD-24
Change in PHQ-9
+12 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Accelerated iTBSExperimental Treatment1 Intervention
In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MagPro X100 Stimulator, B70 Fluid-Cooled Coil
2020
N/A
~210

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
352 Previous Clinical Trials
80,732 Total Patients Enrolled
84 Trials studying Depression
18,955 Patients Enrolled for Depression
Daniel Blumberger, MDPrincipal InvestigatorCAMH
4 Previous Clinical Trials
516 Total Patients Enrolled
3 Trials studying Depression
489 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic
Daniel Blumberger 2020. "Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04384965.
~36 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top